Steve Frost
About
Steve Frost is from London, England, United Kingdom. Steve is currently Portolio Manager - Alpha Capture at Almace Asset Management, located in Greater London. Steve also works as Proprietary Equity portfolio manager - self employed at undefined, a job Steve has held since Jun 2025. In Steve's previous role as a Global Equity Long Short SMID GARP Portfolio Manager at TH Global Capital, Steve worked in London Area, United Kingdom until Apr 2025. Prior to joining TH Global Capital, Steve was a Consultant at Argonaut Capital Partners LLP and held the position of Consultant at London Area, United Kingdom. Prior to that, Steve was a Consultant at DRUGANALYST LIMITED, based in London Area, United Kingdom from Apr 2024 to Jul 2024. Steve started working as Head of Global Long Short equity strategy at FM Capital Partners Ltd in London, England, United Kingdom in Dec 2021. From Jul 2010 to Jun 2021, Steve was European equity hedge fund lead portfolio manager at Martin Currie, based in London, United Kingdom. Prior to that, Steve was a European equity hedge fund manager / Partner at Sofaer Global Research, based in London, United Kingdom from Aug 2000 to Jun 2010.
Steve Frost's contact information is available for free on finalscout.com, a web-based professional networking database with more than 500 million business contacts and 200 million company profiles.
Steve Frost's current jobs
Managing capital as a Global Long Short Equity strategy.
Steve Frost's past jobs
Portfolio manager of TH GARP, a long short Small-Midcap (SMID) Global Equity fund. Start up project cancelled.
Consultancy role to create a complex quantitative screen for a 3,000 company universe. This involved complex formulas to translate data into a structured framework, to allow efficient screening, analysis (earnings revisions, earnings growth, earnings quality, balance sheet strength, balance sheet working capital efficiency, valuations) and stock selection decision-making. The role involved a comprehensive costing strategy for the model's implementation and maintenance.
Develop and enhance DrugAnalyst's analysis of pharmaceutical company corporate results and DrugAnalyst's client portal. Creation of a model for peak potential of GLP1 / obesity drugs.
Long short global equity strategy utilising a combination of equities and derivatives within an investment universe of large and mid-cap US and European companies. This is underpinned by rigorous bottom up stock analysis to generate excess Alpha complemented with Net exposure management determined by conditions of the credit market, momentum in macro and breadth of opportunities within equities. Exposure ranges : Gross 150-200%, Net -20% and 20%.
European long short equity fund : UCIT, managed accounts, sovereign wealth, market neutral. Average AUM $350m, peak $650m. Focus creating alpha on longs AND shorts through on bottom up stock selection, investment themes with a macro / credit overlay. Gross exposure 100-165%, Net Exposure -5 to +65%.